Lisa is a highly accomplished, sophisticated litigator with a diverse national practice focused on complex mass tort, product liability, class action, business, health care and environmental litigation throughout the country.
Leader of the Product Liability and Mass Tort Litigation Practice Team, co-leader of the Health Care and Life Sciences Team, and co-leader of the Class Action Practice Team, Lisa plays an active role in leading litigation at Phillips Lytle. In addition, she is a member of the firm’s Governing Committee and has served on the firm’s Strategic Planning Committees throughout her time at the firm.
Lisa has extensive experience and a successful track record handling complex, high-profile litigation, including class actions, multi-district litigation, and disputes involving numerous parties. Lisa has successfully defended hundreds of mass tort and product liability cases for global manufacturers of pharmaceutical, medical device, chemical, and consumer products, as well as retailers of consumer products, serving as national, regional, and local counsel in federal and state courts throughout the United States. Major companies facing their toughest litigation and reputational challenges turn to Lisa to defend the litigation and serve as a trusted strategic advisor.
Lisa’s deep and sophisticated national experience is the basis for providing her clients with aggressive, proactive, strategic defenses and risk mitigation, as demonstrated by Lisa’s record of achieving early successful motions to dismiss in class actions and other complex litigation, as well as developing other effective, bespoke exit strategies.
Lisa has successfully defended manufacturers, hospitals, and financial institutions in consumer class actions across the country, including product liability, data privacy, bank overdraft fee, and alleged deceptive business practices class actions. Lisa is also known for her exceptional negotiation skills and has been retained to serve in niche roles such as settlement counsel in national consumer class action and multi-district litigation, as well as in individual cases involving catastrophic injury or death.
In the healthcare arena, Lisa represents hospital systems and healthcare providers in governmental investigations by DOJ and Attorneys General, and whistleblower actions, involving alleged False Claims Act and other statutory violations.
In addition to serving in many leadership roles at the firm, Lisa is also a leader in the profession and the community, serving by appointment on the New York State Bar Association Task Force on Opioid Addiction, and serving on the boards of directors and trustees of significant arts and cultural institutions, the largest charter school in New York State, and a 501(c)(3) cancer charity she co-founded, which has assisted over 12,000 cancer patients.
Co-Author, “Understanding Cybersecurity Trends and the New NYSDOH Hospital Regulations,” Rochester Business Journal, January 2025
Co-Author, “Navigating Decentralized Clinical Trials With FSA’s Guidance,” Law360, November 2024
Co-Author, “What’s Next for MDMA? Clinicians, Researchers and Congressional Lawmakers Urge FDA to Approve MDMA for PTSD Despite a Negative Vote by FDA’s Advisory Committee” New York Law Journal, August 2024
Co-Author, “Major Milestone for Psychedelic-Assisted Therapy: Lykos Therapeutics Submits New Drug Application to the FDA for MDMA-Assisted Therapy for PTSD,” New York Law Journal, January 2024
Co-Author, “Amended Federal Rule 702 and Expert Admissibility: A Rule That Hit the Ground Running,” The National Law Review, December 2023
Co-Author, “FDA Draft Guidance on Clinical Trials for Psychedelics: A Closer Look,” Microdose.buzz, July 2023
Co-Author, “FDA Issues Draft Guidance on Diversity and Inclusion in Clinical Trials,” National Law Review, August 2022
Co-Author, “Everyday Epidemiology: How the Pandemic Brought Science to the Forefront of Public Consciousness,” Buffalo Business First, March 2022
Co-Author, “Cannabis Forethought: Labeling, Warnings and Risk Mitigation,” Buffalo Business First, February 2022
Co-Author, “How Medical Device Cos. Can Limit Enforcement, Legal Risks,” Law360, December 2021
Co-Author, “Baby Food Contamination Cases Face Class Action Hurdles,” Law360, June 2021
Co-Author, “Freedom to Innovate: Lessons From the COVID-19 Pandemic,” Buffalo Business First, March 2021
Want to Know More?
Receive firm communications, legal news and industry alerts delivered to your inbox.
